Skip to main content
      Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019. #1223  ALLN-346 a urate degrading enzyme in a pig model of gout L06 Emapalumab for…
      SJIA-associated ILD: Dr. Jonathan Hausmann
      Dr. Hausmann describes a new inflammatory lung disease at the 2019 ACR/ARP annual meeting in Atlanta.
      Inflammatory Arthritis Persists After Immunotherapy Cessation: Dr. David Liew
      Dr. Liew discusses abstract #1808 Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
      Studies on the Changing Face of RA: Dr. Janet Pope
      Dr. Pope discusses abstract #171, #172 and #841 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
      Panel Presentation: Rheumatoid Arthritis
      Drs. Jack Cush, Arthur Kavanaugh and Jonathan Kay discuss several rheumatoid arthritis studies presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Abstracts discussed include abstract #1342, #1350, #1160, and more.
      Safety of Methotrexate (The CIRT Trial): Dr. Jack Cush
      Dr. Cush discusses abstract #1890 on the CIRT trial as presented at the 2019 ACR/ARP annual meeting in Atlanta.
      The Risk RA Prospective Study: Dr. Jonathan Kay
      Dr. Kay discusses abstract #1758 presented during a plenary session at the 2019 ACR/ARP annual meeting in Atlanta.
      Antimalarials in RA: Dr. Janet Pope
      Dr. Janet Pope discusses two abstracts - #1891 and #896 - regarding hydroxychloroquine in RA at the 2019 ACR/ARP annual meeting in Atlanta.
      Welcome to ACR 2019: Dr. Jack Cush
      Dr. Jack Cush gives an overview of RheumNow's 2019 ACR/ARP annual meeting coverage in Atlanta.
      Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Study of ANA+ people without lupus or CTD shows that fatigue does not increase odds of having lupus or CTD.…
      ×